Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-27T00:52:30.928Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparisons of Clinical Efficacy

Published online by Cambridge University Press:  06 August 2018

I. N. Ferrier
I. N. Ferrier*
Affiliation:
Division of Psychiatry, School of Neurosciences, University of Newcastle, Newcastle upon Tyne NE1 4LP
Get access Rights & Permissions [Opens in a new window]

Extract

This paper does not attempt to review the whole topic of clinical efficacy but will consider general concepts, particularly in the light of the advent of the serotonin (5-HT) uptake inhibitors (SSRIs).

The aetiology of depression is complex. In most cases there is some form of predisposition based on problematical family dynamics, disordered family communication and/or genetic factors; each may be present to a variable extent. On top of this predisposition, some form of stimulus - ‘stress’, an external problem, loss of control, a physical disorder, adverse life circumstances - appears to affect those who are already primed. There are a variety of possible outcomes from this combination of predisposition and stimuli: low mood, depression in the full syndromic sense, and depression with biological features. It seems likely that, particularly with severe depressions (the major syndromic forms and those with biological features), there are neuroendocrine and neurochemical changes to mediate the effects of stress into those of the clinical symptoms and signs. It has been hypothesised that stressors induce adaptive neurochemical changes, failure of which may engender behavioural disturbances (Anisman & Zacharko, 1992). However, there are also many individuals who may not undergo this process, but who probably have some cognitive or learned change leading to dysphoria; this aspect needs to be considered carefully in relation to efficacy.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 163 , Issue S20: The Economic Evaluation of Antidepressant Drug Therapy , July 1993 , pp. 25 - 28
Copyright
Copyright © 1993 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anisman, H. & Zacharko, R. M. (1992) Depression as a consequence of inadequate neurochemical adaptation in response to stressors. British Journal of Psychiatry, 160 (suppl. 15), 36–43 Google Scholar
Arango, V., Ernsberger, P., Marzuk, P.M., et al (1990) Autoradiographic demonstration of increased serotonin 5-HT2 and β-adrenergic receptor binding sites in the brains of suicide victims. Archives of General Psychiatry, 47, 1038–1047.Google Scholar
Barker, W., Scott, J. & Eccleston, D. (1987) The Newcastle chronic depression study: results of a treatment regime. International Clinical Psychopharmacology, 2, 261–272.Google Scholar
Blier, P., de Montigny, C. & Chaput, Y. (1987) Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. Journal of Clinical Psychopharmacology, 7 (suppl. 6), 245–355.Google Scholar
Charney, D. S., Menkes, D. B. & Heninger, G. R. (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the aetiology and the therapy of depression. Archives of General Psychiatry, 38, 1160–1180.Google Scholar
Coppen, A. (1967) The biochemistry of the affective disorders. British Journal of Psychiatry, 113, 1237–1264.Google Scholar
Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology, 90, 131–138.Google Scholar
Danish University Antidepressant Group (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 18, 289–299.CrossRefGoogle Scholar
Delgado, P. L., Charney, D. S., Price, L. H., et al (1990) Serotonin function and the mechanism of antidepressant action. Archives of General Psychiatry, 47, 411–418.Google Scholar
Dunbar, G. C. (1991) Paroxetine in the treatment of severe (melancholic) depression. Biological Psychiatry, 28, 235S.Google Scholar
Ferrier, I. N., Eccleston, D., Moore, P. B., et al (1990) Relapse of chronic depressives on withdrawal of L-tryptophan. Lancet, 336, 380–381.Google Scholar
Frank, E., Kupfer, D. J., Perel, J. M., et al (1990) Three year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 1093–1099.Google Scholar
Fuger, J., Zinner, H.-J., Kasper, S., et al (1993) Efficacy of the new generation antidepressants - a statistical meta-analysis. Pharmacopsychiatry (in press).Google Scholar
Goodwin, G. M., Green, A. R. & Johnson, P. (1984) 5-HT receptor characteristics in frontal cortex and 5-HT2 receptor mediated head twitch behaviour following antidepressant treatment to mice. British Journal of Pharmacology, 83, 235–242.Google Scholar
Hale, A., Proctor, A. W. & Bridges, P. K. (1987) Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies. British Journal of Psychiatry, 143, 213–217.CrossRefGoogle Scholar
Hertzman, P. A., Blevine, W. L., Mayer, J., et al (1990) Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. New England Journal of Medicine, 322, 869–873.Google Scholar
Kasper, J., Fuger, J. & Moller, H.-J. (1992) Comparative efficacy of antidepressants. Drugs, 43 (suppl. 2), 11–23.CrossRefGoogle ScholarPubMed
Leonard, B. E. (1992) Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs, 43, (suppl. 2), 3–10.Google Scholar
McEwan, B. S., Gould, E. A. & Sakai, R. R. (1992) The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. British Journal of Psychiatry, 160 (suppl. 15), 18–24.Google Scholar
Meats, P., Timol, M. & Jolley, D. (1991) Prognosis of depression in the elderly. British Journal of Psychiatry, 159, 659–663.Google Scholar
Meltzer, H. Y. (1989) Serotonergic dysfunction in depression. British Journal of Psychiatry, 155 (suppl. 8), 25–31.Google Scholar
Muller, E. A., Murphy, D. L. & Sunderland, T. (1985) Neuroendocrine effects of m-chlorophenylpiperazine; a serotonin agonist in humans. Journal of Clinical Endocrinology and Metabolism, 61, 1179–1189.Google Scholar
Old Age Depression Interest Group (1993) How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. British Journal of Psychiatry, 162, 175–182.Google Scholar
Ottevanger, E. A. (1991) The efficacy of fluvoxamine in patients with severe depression. British Journal of Clinical Research, 2, 125–132.Google Scholar
Shopsin, B., Friedman, E. & Gershon, S. (1976) Parachlor-phenylalanine reversal of tranylcypromine effects in depressed patients. Archives of General Psychiatry, 33, 811–819.Google Scholar
Sulser, F. (1986) Update on neuroreceptor mechanisms and their implications for the pharmacotherapy of affective disorders. Journal of Clinical Psychiatry, 47 (suppl. 10), 13–18.Google Scholar
Swinbanks, D. & Anderson, C. (1992) Search for contaminant in EMS outbreak goes slowly. Nature, 358, 96.Google Scholar
Tyrer, P., Marsden, C. A., Casey, P. et al (1987) Clinical efficacy of paroxetine in resistant depression. Journal of Psychopharmacology, 1, 251–257.Google Scholar
Yates, M., Leake, A., Candy, J. M. et al (1990) 5-HT2 receptor changes in major depression. Biological Psychiatry, 27, 489–496.Google Scholar
Young, S. N., Pihl, R. O. & Erwin, F. R. (1986) The effect of altered tryptophan levels on mood and behaviour in normal human males. Clinical Neuropharmacology, 9 (suppl. 4), 516–518.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.